| [1] to the rescue.
Function
CD55 or decay-accelerating factor (DAF) serves as an inhibitor of the complement system. It is broadly expressed in malignant tumors[2].
Disease
CD55 mutations are related to early-onset protein-losing enteropathy and thrombosis[3].
Relevance
CD55 is involved in promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, evasion of apoptosis, cell motility and metastais. CD55 is included in diagnostic or therapeutic studies.
Structural highlights
- ↑ Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
- ↑ Mikesch JH, Buerger H, Simon R, Brandt B. Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies. Biochim Biophys Acta. 2006 Aug;1766(1):42-52. doi: 10.1016/j.bbcan.2006.04.001., Epub 2006 May 9. PMID:16784816 doi:https://dx.doi.org/10.1016/j.bbcan.2006.04.001
- ↑ Ozen A, Comrie WA, Ardy RC, Dominguez Conde C, Dalgic B, Beser OF, Morawski AR, Karakoc-Aydiner E, Tutar E, Baris S, Ozcay F, Serwas NK, Zhang Y, Matthews HF, Pittaluga S, Folio LR, Unlusoy Aksu A, McElwee JJ, Krolo A, Kiykim A, Baris Z, Gulsan M, Ogulur I, Snapper SB, Houwen RHJ, Leavis HL, Ertem D, Kain R, Sari S, Erkan T, Su HC, Boztug K, Lenardo MJ. CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis. N Engl J Med. 2017 Jul 6;377(1):52-61. doi: 10.1056/NEJMoa1615887. Epub 2017 Jun , 28. PMID:28657829 doi:https://dx.doi.org/10.1056/NEJMoa1615887
|
3D structures of CD55
Updated on 31-October-2018
3j24 - hCD55 - human - Cryo EM
1ojv, 1ojw, 1ojy, 1ok1, 1ok2, 1ok3, 1ok9 - hCD55
1nwv - hCD55 - NMR
1uot, 1h03, 1h2p, 1h2q, 1h04 - hCD55 domains 3,4
3iyp, 2c8i, 1upn - hCD55 + echovirus - Cryo EM
5foa - hCD55 + complement C3 + complement C3B
References
